This company has been acquired
LogicBio Therapeutics Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
-18.2%
Tasa de crecimiento de los beneficios
46.0%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs | 17.0% |
Tasa de crecimiento de los ingresos | 77.0% |
Rentabilidad financiera | -168.7% |
Margen neto | -246.7% |
Última actualización de beneficios | 30 Sep 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
Jan 11Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Aug 18LogicBio EPS misses by $0.06, beats on revenue
May 10LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo
Apr 27Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?
Apr 12Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?
Mar 08The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More
Jan 15LogicBio extends collaboration with Children's Medical Research Institute
Jan 07LogicBio Therapeutics names new CFO
Dec 22Looking In On LogicBio
Nov 17LogicBio reports Q3 results
Nov 09Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero LogicBio Therapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Sep 22 | 11 | -27 | 14 | -8 |
30 Jun 22 | 10 | -31 | 15 | 0 |
31 Mar 22 | 8 | -36 | 16 | -1 |
31 Dec 21 | 5 | -40 | 16 | 0 |
30 Sep 21 | 4 | -38 | 15 | 8 |
30 Jun 21 | 3 | -36 | 14 | 1 |
31 Mar 21 | 3 | -33 | 13 | -1 |
31 Dec 20 | 3 | -33 | 12 | 0 |
30 Sep 20 | 3 | -37 | 12 | 8 |
30 Jun 20 | 2 | -40 | 11 | 17 |
31 Mar 20 | 1 | -42 | 11 | 32 |
31 Dec 19 | 0 | -40 | 10 | 31 |
30 Sep 19 | 0 | -32 | 10 | 27 |
30 Jun 19 | 0 | -29 | 10 | 21 |
31 Mar 19 | 0 | -23 | 9 | 15 |
31 Dec 18 | 0 | -18 | 7 | 11 |
30 Sep 18 | 0 | -18 | 5 | 8 |
30 Jun 18 | 0 | -11 | 4 | 6 |
31 Mar 18 | 0 | -9 | 3 | 5 |
31 Dec 17 | 0 | -8 | 2 | 4 |
Ingresos de calidad: LOGC is currently unprofitable.
Margen de beneficios creciente: LOGC is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: LOGC is unprofitable, and losses have increased over the past 5 years at a rate of 18.2% per year.
Acelerando crecimiento: Unable to compare LOGC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: LOGC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (60.8%).
Rentabilidad financiera
Alta ROE: LOGC has a negative Return on Equity (-168.65%), as it is currently unprofitable.